Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
23 août 2021 11h55 HE
|
BioNTech SE
COMIRNATY is the first COVID-19 vaccine to be granted FDA approval Approval is based on a comprehensive submission package including six-month efficacy and safety data after second doseMore than 1.2...
PRVB BREAKING ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline – PRVB
04 juin 2021 19h15 HE
|
The Rosen Law Firm PA
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2,...
Immunocore Reports First Quarter 2021 Financial Results
12 mai 2021 07h00 HE
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports First Quarter 2021 Financial Results Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) is expected to be completed in...
Pfizer und BioNTech beginnen rollierenden Einreichungsprozess einer Biologics License Application für die volle Zulassung ihres COVID-19-Impfstoffs bei der FDA
07 mai 2021 06h45 HE
|
BioNTech SE
NEW YORK, USA und MAINZ, DEUTSCHLAND, 07. Mai 2021 —Pfizer Inc. (NYSE: PFE) und BioNTech SE (Nasdaq: BNTX) gaben heute bekannt, dass sie die Einreichung des Antrags für die vollständige Zulassung...
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of their COVID-19 Vaccine
07 mai 2021 06h45 HE
|
BioNTech SE
NEW YORK and MAINZ, GERMANY, May 7, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a Biologics License Application (BLA) with the U.S....
Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
10 févr. 2021 16h05 HE
|
Genmab A/S
Company Announcement Submission based on positive pivotal innovaTV 204 trial results presented at the European Society of Medical Oncology Virtual Congress 2020 COPENHAGEN, Denmark and BOTHELL,...
ROSEN, TRUSTED INVESTOR COUNSEL, Reminds BioMarin Pharmaceutical Inc. Investors of Important Deadline in Securities Class Action – BMRN
25 oct. 2020 12h42 HE
|
The Rosen Law Firm PA
NEW YORK, Oct. 25, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between February...
ElsaLys Biotech annonce l'acceptation par la FDA du dépôt de sa demande de mise sur le marché pour LEUKOTAC® (inolimomab) pour le traitement de la maladie du greffon contre l'hôte chez l’adulte
23 juil. 2020 08h00 HE
|
Elsalys Biotech
ElsaLys Biotech annonce l'acceptation par la FDA du dépôt de sa demande de mise sur le marché pour LEUKOTAC® (inolimomab) pour le traitement de la maladie du greffon contre l'hôte chez l’adulte...
ElsaLys Biotech announces submission of Biologics License Application to FDA for LEUKOTAC® (inolimomab) for the treatment of graft-versus-host disease in adult patients
23 juil. 2020 08h00 HE
|
Elsalys Biotech
ElsaLys Biotech announces submission of Biologics License Application to FDA for LEUKOTAC® (inolimomab) for the treatment of graft-versus-host disease in adult patients ·The Biologics License...